Subarachnoid hemorrhage medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 24: | Line 24: | ||
**Euvolemia | **Euvolemia | ||
**Normal electrolyte balance (avoid hyponatremia) | **Normal electrolyte balance (avoid hyponatremia) | ||
*Antithrombotic discontinuation | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" | ''' | | style="padding: 5px 5px; background: #DCDCDC;" | '''[[intracranial pressure|Increased intracranial pressure (ICP)]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* | *Place a ventriculostomy | ||
**Direct measurement of [[intracranial pressure|intracranial pressure (ICP]]) | |||
**Drainage of [[CSF]] | |||
*Osmotic therapy and diuresis | |||
*Avoid hyperventilation hyperventilation can result in exacerbate [[vasospasm]] | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" | ''' | | style="padding: 5px 5px; background: #DCDCDC;" | '''Blood pressure control | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* | *No clear targeted blood pressure is defined | ||
*Decrease in systolic blood pressure to <160mm Hg | |||
*Preferred regimen | |||
**[[Labetalol]] | |||
**[[Nicardipine]] | |||
**[[Enalapril]] | |||
*Decrease in systolic blood pressure to <160mm Hg | |||
*[[Nitroprusside]] or [[nitroglycerin]] should be avoided (possible increase intracranial pressure) | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" | ''' | | style="padding: 5px 5px; background: #DCDCDC;" | ''' | ||
Line 46: | Line 58: | ||
|MedCond = Subarachnoid hemorrhage|Alteplase}} | |MedCond = Subarachnoid hemorrhage|Alteplase}} | ||
==2012 AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage<ref name=aSAH>Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage http://stroke.ahajournals.org/content/early/2012/05/03/STR.0b013e3182587839 </ref>== | |||
===Management of Hydrocephalus Associated With aSAH: Recommendations=== | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' aSAH-associated acute symptomatic hydrocephalus should be managed by cerebrospinal fluid diversion (EVD or lumbar drainage, depending on the clinical scenario) ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' aSAH-associated chronic symptomatic hydrocepha- lus should be treated with permanent cerebrospinal fluid diversion ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|} | |||
{|class="wikitable" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm) | |||
|- | |||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Weaning EVD over >24 hours does not appear to be effective in reducing the need for ventricular shunting ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|- | |||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''2.''' Routine fenestration of the lamina terminalis is not useful for reducing the rate of shunt-dependent hydrocephalus and therefore should not be routinely performed. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|} | |||
==References== | ==References== |
Revision as of 19:08, 14 December 2016
Subarachnoid Hemorrhage Microchapters |
Diagnosis |
---|
Treatment |
AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage (2012)
|
Case Studies |
Subarachnoid hemorrhage medical therapy On the Web |
American Roentgen Ray Society Images of Subarachnoid hemorrhage medical therapy |
Risk calculators and risk factors for Subarachnoid hemorrhage medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Sara Mehrsefat, M.D. [3]
Overview
Medical Therapy
The first priority is stabilization of the patient. In those with a depressed level of consciousness, intubation and mechanical ventilation may be required. Blood pressure, pulse, respiratory rate and Glasgow Coma Scale are monitored frequently. Once the diagnosis is confirmed, admission to an intensive care unit (ICU) may be considered preferable, especially given that 15% have a further episode (rebleeding) in the first hours after admission. Nutrition is an early priority, with oral or nasogastric tube feeding being preferable over parenteral routes. Analgesia (pain control) is generally restricted to non-sedating agents, as sedation would interfere with the monitoring of the level of consciousness. There is emphasis on the prevention of complications; for instance, deep vein thrombosis is prevented with compression stockings and/or intermittent pneumatic compression.
Medical Condition | Management |
---|---|
First 24h of admission |
|
Increased intracranial pressure (ICP) |
|
Blood pressure control |
|
|
Prevention of Vasospasm
Vasospasm is a serious complication of SAH. It may be seen in 50% of SAH patients studied with angiography, and is symptomatic roughly 30% of the time. This condition can be verified by transcranial doppler or cerebral angiography, and can cause ischemic brain injury that can cause permanent brain damage, and if severe can be fatal. Nimodipine, an oral calcium channel blocker, has been shown to reduce the chance of a bad outcome, even if it does not significantly reduce the amount of angiographic vasospasm.[1][2]
Follow-Up
A patient who recovers without immediate intervention may receive follow-up angiography to identify aneurysms which may be amenable to either surgical clipping or endovascular coiling to prevent recurrent episodes of SAH.
Contraindicated medications
Subarachnoid hemorrhage is considered an absolute contraindication to the use of the following medications:
2012 AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage[3]
Management of Hydrocephalus Associated With aSAH: Recommendations
Class I |
"1. aSAH-associated acute symptomatic hydrocephalus should be managed by cerebrospinal fluid diversion (EVD or lumbar drainage, depending on the clinical scenario) (Level of Evidence: B)" |
"2. aSAH-associated chronic symptomatic hydrocepha- lus should be treated with permanent cerebrospinal fluid diversion (Level of Evidence: C)" |
Class III (Harm) |
"1. Weaning EVD over >24 hours does not appear to be effective in reducing the need for ventricular shunting (Level of Evidence: B)" |
"2. Routine fenestration of the lamina terminalis is not useful for reducing the rate of shunt-dependent hydrocephalus and therefore should not be routinely performed. (Level of Evidence: B)" |
References
- ↑ Allen GS, Ahn HS, Preziosi TJ; et al. (1983). "Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage". N. Engl. J. Med. 308 (11): 619–24. PMID 6338383.
- ↑ Dorhout Mees S, Rinkel G, Feigin V; et al. (2007). "Calcium antagonists for aneurysmal subarachnoid haemorrhage". Cochrane database of systematic reviews (Online) (3): CD000277. doi:10.1002/14651858.CD000277.pub3. PMID 17636626.
- ↑ Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage http://stroke.ahajournals.org/content/early/2012/05/03/STR.0b013e3182587839
]